We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: hepatocellular carcinoma
MedXY News
EnglishTag

hepatocellular carcinoma

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Uncoupling Metabolic Reprogramming in Hepatocellular Carcinoma: The JOSD1-PGAM1 Ubiquitination-Lactylation Switch
Clinical UpdatesGlycolysishepatocellular carcinoma

Uncoupling Metabolic Reprogramming in Hepatocellular Carcinoma: The JOSD1-PGAM1 Ubiquitination-Lactylation Switch

By MedXY|May 1, 2026

This article explores how the deubiquitinase JOSD1 drives HCC progression by modulating a novel PTM switch on PGAM1, promoting glycolysis and immune evasion while providing a new target for combined immunotherapy.

A New Framework to Refine Hepatocellular Cancer Surveillance with Risk Stratification Models
Gastroenterologycirrhosishepatocellular carcinoma

A New Framework to Refine Hepatocellular Cancer Surveillance with Risk Stratification Models

By MedXY|Apr 23, 2026

The Translational Liver Cancer Consortium proposes a structured framework for developing and validating risk models to optimize HCC surveillance, addressing gaps in current clinical guidelines.

Perioperative Nivolumab Combined with Irreversible Electroporation Shows Antitumoral Effect in High-Risk BCLC A Hepatocellular Carcinoma: Results from the NIVOLEP Phase 2 Trial
Gastroenterologyablation therapyhepatocellular carcinoma

Perioperative Nivolumab Combined with Irreversible Electroporation Shows Antitumoral Effect in High-Risk BCLC A Hepatocellular Carcinoma: Results from the NIVOLEP Phase 2 Trial

By MedXY|Apr 14, 2026

The NIVOLEP phase 2 trial demonstrates that perioperative nivolumab (neoadjuvant and adjuvant) combined with irreversible electroporation achieves 70.6% one-year local recurrence-free survival in BCLC A HCC patients with high recurrence ris

Beyond Simple Quantification: How AI and Tumor-Stroma Ratio Are Redefining Prognosis Prediction in Hepatocellular Carcinoma
newsartificial intelligenceComputational Pathology

Beyond Simple Quantification: How AI and Tumor-Stroma Ratio Are Redefining Prognosis Prediction in Hepatocellular Carcinoma

By MedXY|Apr 9, 2026

Researchers have developed an AI-powered framework that uncovers a non-linear relationship between tumor-stroma ratio and mortality in hepatocellular carcinoma, using a novel token-guided multimodal fusion approach to improve prognostic acc

The Gut-Liver Axis Unveiled: How Microbiome Signatures Track Disease Progression from Fatty Liver to Cancer
Gastroenterologybiomarkersgut-liver axis

The Gut-Liver Axis Unveiled: How Microbiome Signatures Track Disease Progression from Fatty Liver to Cancer

By MedXY|Apr 5, 2026

A landmark multicohort study of 1,168 individuals reveals that gut microbiome diversity systematically declines across liver disease stages, with specific bacterial markers like Veillonella and functional metabolic shifts predicting disease

Novel Fusion Model Combines Hypoxia and Immune Signatures to Predict Survival in HCC Patients Undergoing TACE Therapy
Gastroenterologyfusion modelhepatocellular carcinoma

Novel Fusion Model Combines Hypoxia and Immune Signatures to Predict Survival in HCC Patients Undergoing TACE Therapy

By MedXY|Apr 2, 2026

A groundbreaking multicentre study develops a clinical-radiologic model integrating hypoxia and immune phenotype signatures to accurately predict prognosis in hepatocellular carcinoma patients treated with transarterial chemoembolisation, p

Predictive Power of MRI-Based Radiomic Dynamics for Pathological Complete Response in Hepatocellular Carcinoma: A Deep Learning Synthesis
Clinical Updatesdeep learninghepatocellular carcinoma

Predictive Power of MRI-Based Radiomic Dynamics for Pathological Complete Response in Hepatocellular Carcinoma: A Deep Learning Synthesis

By MedXY|Mar 15, 2026

This review evaluates how deep learning-assisted delta radiomics on MRI, combined with AFP response, provides a non-invasive, high-accuracy prediction of pathological complete response in unresectable HCC undergoing conversion immunotherapy

Balancing the Scales: The FYN/LCK Kinase Switch Rescues Progenitor T Cells to Overcome Immunotherapy Resistance in Hepatocellular Carcinoma
Gastroenterologyhepatocellular carcinomaimmunotherapy

Balancing the Scales: The FYN/LCK Kinase Switch Rescues Progenitor T Cells to Overcome Immunotherapy Resistance in Hepatocellular Carcinoma

By MedXY|Mar 12, 2026

A breakthrough study reveals that the balance between FYN and LCK kinases acts as a metabolic switch in hepatocellular carcinoma. By modulating this axis through low-dose LCK inhibition, researchers successfully preserved T-cell stemness an

Toxicity as a Proxy for Efficacy: How Immune-Mediated Adverse Events Correlate with Survival in the HIMALAYA Trial
Gastroenterologyhepatocellular carcinomaHIMALAYA Trial

Toxicity as a Proxy for Efficacy: How Immune-Mediated Adverse Events Correlate with Survival in the HIMALAYA Trial

By MedXY|Mar 11, 2026

This post-hoc analysis of the HIMALAYA Phase III trial explores the link between immune-mediated adverse events and overall survival in unresectable HCC, revealing that patients on the STRIDE regimen who experienced imAEs had improved survi

TAF2 in Hepatocellular Homeostasis and Tumorigenesis: Navigating the 8q24.12 Amplicon in Liver Cancer
Clinical Updates8q24.12 Amplificationhepatocellular carcinoma

TAF2 in Hepatocellular Homeostasis and Tumorigenesis: Navigating the 8q24.12 Amplicon in Liver Cancer

By MedXY|Mar 11, 2026

This review explores the dual role of TAF2 as a basal transcription factor essential for hepatocyte survival and an oncogenic driver in hepatocellular carcinoma when overexpressed via 8q24.12 amplification.

Unmasking DARS1: A Dual-Action Driver of Hepatocellular Carcinoma Aggressiveness via SAGA-MYC Signaling
Gastroenterologyhepatocellular carcinomaliquid biopsy

Unmasking DARS1: A Dual-Action Driver of Hepatocellular Carcinoma Aggressiveness via SAGA-MYC Signaling

By MedXY|Mar 8, 2026

Researchers have identified DARS1 as a critical oncogenic driver in hepatocellular carcinoma. Beyond its role in protein synthesis, DARS1 enters the nucleus to modulate MYC signaling through the SAGA complex, offering a new therapeutic vuln

Antiviral Prophylaxis Levels the Playing Field: Safe ICI Use in High-Viral Load HBV-HCC Patients
Gastroenterologyantiviral prophylaxishepatocellular carcinoma

Antiviral Prophylaxis Levels the Playing Field: Safe ICI Use in High-Viral Load HBV-HCC Patients

By MedXY|Jan 12, 2026

A prospective study demonstrates that concurrent antiviral prophylaxis effectively mitigates HBV reactivation risk in HCC patients treated with PD-1/L1 inhibitors, regardless of baseline viral load, challenging traditional clinical trial ex

Atezolizumab–Bevacizumab Provides the Best Balance of Survival and Quality of Life in First‑Line Advanced Hepatocellular Carcinoma
newshepatocellular carcinomaimmunotherapy

Atezolizumab–Bevacizumab Provides the Best Balance of Survival and Quality of Life in First‑Line Advanced Hepatocellular Carcinoma

By MedXY|Dec 14, 2025

A Bayesian network meta-analysis integrating health‑related quality of life and overall survival across first‑line trials in advanced hepatocellular carcinoma shows atezolizumab plus bevacizumab provides the most favorable combined patient‑

Camrelizumab plus Rivoceranib Delivers Substantial Survival Gain over Sorafenib in First‑line Unresectable HCC: Final CARES‑310 Results
newshepatocellular carcinomaimmunotherapy

Camrelizumab plus Rivoceranib Delivers Substantial Survival Gain over Sorafenib in First‑line Unresectable HCC: Final CARES‑310 Results

By MedXY|Nov 30, 2025

Final CARES-310 analysis shows camrelizumab plus rivoceranib significantly improves overall survival versus sorafenib in first-line unresectable hepatocellular carcinoma, with increased but manageable toxicity. Results support the combinati

Immune-related adverse events strongly predict early graft rejection after liver transplant in HCC patients treated with checkpoint inhibitors
Gastroenterologygraft rejectionhepatocellular carcinoma

Immune-related adverse events strongly predict early graft rejection after liver transplant in HCC patients treated with checkpoint inhibitors

By MedXY|Nov 6, 2025

A multicentre retrospective cohort found that pretransplant immune-related adverse events (irAEs) markedly increase the risk of early liver allograft rejection after liver transplantation for hepatocellular carcinoma (HCC). IrAEs, short ICI

Perioperative Camrelizumab Plus Rivoceranib Enhances Event-Free Survival in High-Risk Resectable Hepatocellular Carcinoma
newscamrelizumabEvent-free survival

Perioperative Camrelizumab Plus Rivoceranib Enhances Event-Free Survival in High-Risk Resectable Hepatocellular Carcinoma

By MedXY|Oct 30, 2025

In the phase 3 CARES-009 trial, perioperative camrelizumab combined with rivoceranib significantly improved event-free survival and major pathological response in patients with resectable high-risk hepatocellular carcinoma, compared to surg

Liver Resection Post Atezo/Bev Induction Enhances Disease Control in Locally Advanced Hepatocellular Carcinoma
newsatezolizumabbevacizumab

Liver Resection Post Atezo/Bev Induction Enhances Disease Control in Locally Advanced Hepatocellular Carcinoma

By MedXY|Oct 30, 2025

Phase 3 TALENTop trial interim results show liver resection following atezolizumab plus bevacizumab induction significantly prolongs time to treatment failure in advanced HCC without extrahepatic spread.

Innovative TCR T-Cell Therapy Shows Promise in Advanced Hepatocellular and Gastric Hepatoid Carcinoma
Gastroenterologyhepatocellular carcinoma

Innovative TCR T-Cell Therapy Shows Promise in Advanced Hepatocellular and Gastric Hepatoid Carcinoma

By MedXY|Oct 28, 2025

A phase I trial reveals that ADP-A2AFP TCR T-cell therapy, targeting AFP-expressing advanced hepatocellular carcinoma and gastric hepatoid carcinoma, is safe and exhibits early antitumor activity in patients refractory to conventional treat

Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma: Long-Term Outcomes and Immunological Biomarkers
newshepatocellular carcinomaimmunotherapy

Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma: Long-Term Outcomes and Immunological Biomarkers

By MedXY|Oct 28, 2025

Neoadjuvant nivolumab combined with ipilimumab shows promising long-term survival and safety in potentially resectable hepatocellular carcinoma, with immunotherapy-induced tertiary lymphoid structures correlating with response.

Navigating Non-Proportional Hazards in Hepatocellular Carcinoma Trials: Enhancing Interim Analysis Accuracy
newsclinical trialshepatocellular carcinoma

Navigating Non-Proportional Hazards in Hepatocellular Carcinoma Trials: Enhancing Interim Analysis Accuracy

By MedXY|Oct 28, 2025

Non-proportional hazards in hepatocellular carcinoma immunotherapy trials can distort interim and final survival outcomes. Employing tailored statistical strategies ensures robust, clinically meaningful analyses and informed decision-making

Prev
2 / 3
123
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities